CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Companyâ€™s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Companyâ€™s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-08-07	US$0.1288	0.00%	269
26-08-06	US$0.1288	-	21,058
26-08-05	US$0.000000	-100.00%	57
26-08-04	US$0.1289	-0.08%	648
26-08-03	US$0.1290	-	3,460

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 10:08:20 2026-08-07 EDT			5-day change	1st Jan Change
0.1288 ^USD	0.00%		-4.59%	-84.85%

06-02	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026	CI
05-15	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	2.65M 2.29M 2.14M 1.96M 3.69M 252M 3.75M 25.09M 9.85M 126M 9.94M 9.72M 418M	P/E 2024	-1.11x	P/E 2025	-0.33x
Enterprise Value	24.5M 21.19M 19.79M 18.16M 34.15M 2.33B 34.69M 232M 91.14M 1.17B 92.01M 89.99M 3.86B	EV / Sales 2024	1.75x	EV / Sales 2025	1.9x
Free-Float	53.62%	Yield 2024 *	-	Yield 2025	-

06-02	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026	CI
05-15	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-14	CASI Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
04-20	CASI Pharmaceuticals, Inc. announced that it has received $20 million in funding from ETP Global III Fund LP	CI
04-20	CASI Pharmaceuticals, Inc. Announces Termination of Dr. Alexander A. Zukiwski, MD as Global Chief Medical Officer, Effective April 20, 2026	CI
03-03	CASI Pharmaceuticals, Inc. Announces CEO Changes	CI
03-03	Casi Pharmaceuticals, Inc. Announces Resignation of Director David Cory, Effective March 31, 2026	CI

1 month	-2.20%
3 months	-7.34%
6 months	-86.07%
Current year	-84.85%

CASI Pharmaceuticals, Inc. Stock Nasdaq

Stocks

CASI

KYG1933S1012

Pharmaceuticals

Valuation: CASI Pharmaceuticals, Inc.

Chart: CASI Pharmaceuticals, Inc.

Latest news : CASI Pharmaceuticals, Inc.

Press Releases: CASI Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: CASI Pharmaceuticals, Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

1 week	0.13	0.17
1 month	0.13	0.19
3 years	0.05	8.48
5 years	0.05	17.4
10 years	0.05	88.92

Manager	Title	Age	Since
David Cory CEO	Chief Executive Officer	62	2025-07-20
Kun Qian DFI	Director of Finance/CFO	44	2025-05-15
Chun Hua Wang COO	Chief Operating Officer	54	2016-12-31

Director	Title	Age	Since
Yue Wu BRD	Director/Board Member	62	2013-03-31
Zhen Bo Su BRD	Director/Board Member	50	2023-03-20
Thomas Folinsbee BRD	Director/Board Member	59	2023-03-20

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CASI PHARMACEUTICALS, INC.	0.00%	-4.59%	-91.24%	-94.40%	2.65M
ELI LILLY AND COMPANY	-0.52%	+3.21%	+89.52%	+127.32%	1,057B
JOHNSON & JOHNSON	+0.88%	+1.13%	+49.56%	+49.69%	625B
ABBVIE INC.	+0.89%	-1.95%	+24.23%	+64.44%	435B
ROCHE HOLDING AG	+0.71%	+3.87%	+49.07%	+37.85%	363B
NOVARTIS AG	+0.64%	-0.49%	+33.94%	+40.01%	296B
ASTRAZENECA PLC	+0.39%	-5.83%	+8.92%	+7.85%	249B
AMGEN INC.	+1.51%	+6.69%	+42.58%	+57.57%	222B
NOVO NORDISK A/S	+3.92%	-0.46%	-5.56%	-52.32%	209B
GILEAD SCIENCES, INC.	+1.80%	+2.30%	+11.56%	+66.35%	165B
Average	+1.14%	+0.87%	+21.26%	+30.44%	402.31B
Weighted average by Cap.	+0.66%	+1.22%	+48.72%	+64.63%

	2024	2025
Net sales	28.54M 24.68M 23.05M 21.15M 39.77M 2.72B 40.41M 270M 106M 1.36B 107M 105M 4.5B	20.71M 17.92M 16.73M 15.35M 28.87M 1.97B 29.33M 196M 77.04M 988M 77.78M 76.08M 3.27B
Net income	-39.26M -33.96M -31.71M -29.09M -54.72M -3.74B -55.59M -372M -146M -1.87B -147M -144M -6.19B	-48.06M -41.57M -38.82M -35.61M -66.98M -4.57B -68.05M -455M -179M -2.29B -180M -177M -7.58B
Net Debt	6.05M 5.23M 4.89M 4.48M 8.43M 576M 8.57M 57.34M 22.5M 289M 22.72M 22.22M 954M	21.85M 18.9M 17.65M 16.19M 30.46M 2.08B 30.94M 207M 81.29M 1.04B 82.07M 80.27M 3.45B